Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall
Zepbound generated $1.9 billion in Q4 2024 sales, falling short of analyst expectations510.
For the full year 2024, Zepbound achieved $4.9 billion in sales during its first full year on the market58.
Eli Lilly's overall Q4 2024 revenue increased by 45% to $13.53 billion, driven by strong sales of Mounjaro and Zepbound35.
Mounjaro, Lilly's diabetes treatment, saw sales jump 60% to $3.53 billion in Q4 20245.
For the full year 2024, Mounjaro sales more than doubled to $11.54 billion58.
Eli Lilly's Q4 2024 profit doubled, with net income reaching $4.41 billion5.
The company issued 2025 guidance, projecting revenue between $58.0 billion and $61.0 billion3.
Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 20247.
Analysts expect Zepbound sales to exceed $10 billion in 20255.
Eli Lilly is expanding manufacturing capacity to meet the high demand for its GLP-1 medications7.
Sources:
3. https://www.prnewswire.com/news-releases/lilly-reports-full-q4-2024-financial-results-and-provides-2025-guidance-302369432.html
5. https://www.startribune.com/diabetes-and-obesity-drugs-fuel-eli-lilly-profit-in-the-final-quarter-of-2024/601217998
7. https://www.biospace.com/business/after-lilly-powers-up-zepbound-supply-analyst-wonders-if-build-out-is-over-our-skis